|
ALX Oncology Holdings Inc. (ALXO) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
ALX Oncology Holdings Inc. (ALXO) Bundle
Verbessern Sie Ihre Anlagestrategien mit dem ALXO DCF -Taschenrechner! Erforschen Sie authentische Alx -Onkologie -Finanzdaten, passen Sie Wachstumsprojektionen und -kosten an und beobachten Sie sofort, wie sich diese Modifikationen auf den inneren Wert von ALXO auswirken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.8 | 1.2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | -75.35 | -100 | 0 | 0 | -43.84 | -43.84 | -43.84 | -43.84 | -43.84 |
| EBITDA | -18.8 | -43.5 | -83.5 | -122.0 | -158.4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | -391.14 | -3676.9 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .4 | .2 | .7 | 1.5 | .8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 8.94 | 17.09 | 100 | 100 | 100 | 65.21 | 65.21 | 65.21 | 65.21 | 65.21 |
| EBIT | -19.2 | -43.7 | -84.2 | -123.4 | -159.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | -400.08 | -3693.99 | 100 | 100 | 100 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 9.0 | 434.2 | 363.7 | 282.9 | 182.7 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 11.18 | 0 | 100 | 100 | 100 | 62.24 | 62.24 | 62.24 | 62.24 | 62.24 |
| Inventories | .0 | .0 | .0 | -17.7 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 3.7 | .0 | 3.8 | 8.1 | 8.6 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 78.15 | 0.33841 | 100 | 100 | 100 | 75.7 | 75.7 | 75.7 | 75.7 | 75.7 |
| Capital Expenditure | -.4 | .0 | -4.9 | -1.4 | -1.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -7.36 | -2.62 | 100 | 100 | 100 | -2 | -2 | -2 | -2 | -2 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -19.2 | -43.9 | -84.2 | -123.5 | -159.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.9 | -46.9 | -84.6 | -101.4 | -176.9 | -8.6 | .0 | .0 | .0 | .0 |
| WACC, % | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 | 8.72 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -8 | |||||||||
| Net Debt | -5 | |||||||||
| Equity Value | -3 | |||||||||
| Diluted Shares Outstanding, MM | 43 | |||||||||
| Equity Value Per Share | -0.06 |
What You Will Get
- Real ALXO Financial Data: Pre-filled with ALX Oncology's historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See ALX Oncology's intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive ALXO Data: Pre-filled with ALX Oncology Holdings Inc.'s historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your parameters.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate various valuation results.
- User-Friendly Interface: Intuitive, organized, and crafted for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review ALX Oncology Holdings Inc.'s (ALXO) pre-filled financial data and forecasts.
- Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment decisions.
Why Choose ALX Oncology Holdings Inc. (ALXO)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs in oncology.
- Strong Research Foundation: Backed by robust clinical data and a team of experienced professionals.
- Commitment to Patients: Focused on improving patient outcomes through targeted treatments.
- Collaborative Approach: Partnerships with leading institutions to enhance research and development.
- Industry Recognition: A trusted name in oncology, known for excellence and integrity in the field.
Who Should Use ALX Oncology Holdings Inc. (ALXO)?
- Investors: Gain insights into the biotech sector with a reliable analysis tool tailored for ALX Oncology Holdings Inc. (ALXO).
- Financial Analysts: Streamline your research with a comprehensive model designed for evaluating ALX Oncology Holdings Inc. (ALXO).
- Consultants: Effortlessly modify the framework for client discussions or strategic presentations related to ALX Oncology Holdings Inc. (ALXO).
- Biotech Enthusiasts: Enhance your knowledge of oncology investments through detailed case studies on ALX Oncology Holdings Inc. (ALXO).
- Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and investment strategies.
What the Template Contains
- Historical Data: Includes ALX Oncology Holdings Inc.'s (ALXO) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate ALX Oncology's (ALXO) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of ALX Oncology Holdings Inc.'s (ALXO) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.